Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
PuraPharm Corp. Ltd. ( (HK:1498) ) has issued an update.
PuraPharm Corporation Limited reported a decline in revenue and an increase in losses for the first half of 2025 compared to the same period in 2024. The company’s revenue decreased by 17% to HK$172,295,000, primarily due to significant drops in the China CCMG and plantation segments. Despite a rise in Chinese healthcare product sales, the overall financial performance was impacted by increased administrative expenses and reduced selling and distribution expenses, leading to a loss of HK$21,806,000 for the period.
The most recent analyst rating on (HK:1498) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on PuraPharm Corp. Ltd. stock, see the HK:1498 Stock Forecast page.
More about PuraPharm Corp. Ltd.
PuraPharm Corporation Limited is a company incorporated in the Cayman Islands, primarily engaged in the production and distribution of Chinese medicine and healthcare products. The company operates in various segments including Chinese concentrated medicine granules (CCMG), Chinese healthcare products, and Chinese medicine clinics, with a market focus in Hong Kong, overseas, and China.
Average Trading Volume: 209,186
Technical Sentiment Signal: Sell
Current Market Cap: HK$183.6M
For a thorough assessment of 1498 stock, go to TipRanks’ Stock Analysis page.